SequelSEC

ALUMIS INC. ALMS

Pharmaceutical Preparations · CIK 0001847367 · Fiscal year ends 1231

Revenue
$24.05M
Fiscal year ended 2025-12-31
Operating income
-$453.80M
Fiscal year ended 2025-12-31
Free cash flow
-$370.18M
Fiscal year ended 2025-12-31

ALUMIS INC. (ALMS) reported revenue of $24.05M and net income of -$243.32M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ALUMIS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ALUMIS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$24.05M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$453.80M
Net income-$243.32M
Research & development$386.00M
Weighted-average diluted sharesshares 85.03M
Pretax income-$251.89M
Income tax expense-$8.56M
Diluted EPS$-2.86
Selling, general & administrativeUnavailable
General & administrative$91.86M
Selling & marketingUnavailable

Balance

ALUMIS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$89.67M
Total assets$411.94M
Current assets$318.23M
Total liabilities$110.64M
Current liabilities$73.32M
Total equity incl. NCI$301.30M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$10.11M

Cash flow

ALUMIS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$369.52M
Capital expenditures$653.00K
Investing cash flow$287.88M
Financing cash flow$2.07M
Net change in cashUnavailable
Stock-based compensation$43.52M
Common dividends paidUnavailable
Common share repurchases$17.00K
Depreciation & amortization$3.50M

Derived

ALUMIS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flow-$370.18M
Gross marginUnavailable
Operating margin-1886.9%
FCF margin-1539.2%
SBC / revenue181.0%
Current ratio4.34x
Revenue YoY growthUnavailable
Net margin-1011.7%
R&D / revenue1605.0%
CapEx / revenue2.7%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALMS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.